Business Standard

Aurobindo Pharma Ltd News

Aurobindo stock at new high, up 5% as board to consider buyback on July 18

In the past one year, the stock has zoomed 89 per cent, as compared to 21 per cent rally in the BSE Sensex.

Aurobindo stock at new high, up 5% as board to consider buyback on July 18
Updated On : 15 Jul 2024 | 10:41 AM IST

Lupin, Eugia recall products from US over manufacturing issues: USFDA

Drugmaker Lupin and a unit of Aurobindo Pharma are recalling products from the American market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), a US-based unit of Lupin is recalling a medication used to treat bacterial infections. Baltimore-based Lupin Pharmaceuticals Inc is recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) due to "failed content uniformity specifications". The affected lot has been produced at the company's Mandideep-based manufacturing plant in Madhya Pradesh. The company commenced the Class II nationwide (US) recall on May 30 this year. The US health regulator stated that New Jersey-based Eugia US LLC, a subsidiary of Aurobindo Pharma, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection USP. The company is recalling the affected lot due to "failed impurities/degradation specifications", USFDA said. Eugia com

Lupin, Eugia recall products from US over manufacturing issues: USFDA
Updated On : 23 Jun 2024 | 11:58 AM IST

Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing

This agreement follows previous disclosures by Aurobindo Pharma about expanding its biologics manufacturing facilities and exploring contract manufacturing operations (CMO) for biologicals

Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing
Updated On : 31 May 2024 | 8:27 PM IST

Aurobindo Pharma stock news: Analysts are bullish despite OAI to Eugia unit

Analysts say that despite OAI on Eugia unit-III, Aurobindo Pharma's Vizag facility may play a back up for unit-III and for new ANDA filings contributing to growth in FY26

Aurobindo Pharma stock news: Analysts are bullish despite OAI to Eugia unit
Updated On : 28 May 2024 | 11:02 AM IST

Aurobindo Pharma Q4 results: PAT rises 79.5% to Rs 908 cr, revenue up 14.8%

The increase in PAT is attributed to expansion into the new markets, product launches and stable pricing

Aurobindo Pharma Q4 results: PAT rises 79.5% to Rs 908 cr, revenue up 14.8%
Updated On : 25 May 2024 | 9:51 PM IST

Aurobindo Pharma gets tax demand of over Rs 13 cr from Hyderabad officials

Aurobindo Pharma Ltd on Friday said it has received tax demand of over Rs 13 crore, including interest and penalty, from the GST authority over ineligible input tax credit claim. The Deputy Commissioner (ST) STU-1 of GST, Punjagutta Division, Hyderabad, Commercial Taxes Department, Telangana, has passed an order under relevant provisions of the Central Goods and Services Tax Act, 2017 and TGST Act 2017 for the FY 2018-19 to this effect. The order demanded reversal of ITC and payment of GST amounting to Rs 6,54,50,645 along with interest of Rs 5,92,20,900 and penalty of Rs 65,51,354, Aurobindo Pharma said in a regulatory filing. It claims ineligible ITC and orders reversal of ITC and demanding GST along with interest, the company added. The company intends to file an appeal before appellate authority, Aurobindo Pharma said, adding there is no material impact on its financials or operations due to the order.

Aurobindo Pharma gets tax demand of over Rs 13 cr from Hyderabad officials
Updated On : 03 May 2024 | 5:54 PM IST

Aurobindo Pharma commissions 4 plants in Andhra including Pen-G facility

Aurobindo Pharma on Monday said it has commissioned four state-of-the-art manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries. Penicillin-G (Pen-G) facility, located in a SEZ at Kakinada in Andhra Pradesh, has a production capacity of 15,000 tonne per annum and also 1.8 lakh tonne of gulcose, while 6-Amino Penicillanic Acid plant has a capacity to produce 3,600 tonne annually, the drug maker said in a press release. The Rs 2,400 crore Pen-G plant is expected to start trial production in April and commercial production in a couple of months and the ramping up of the production will happen during the second quarter of the current fiscal, a senior official of the city-based drug maker had earlier said. The plant was approved under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and Active .

Aurobindo Pharma commissions 4 plants in Andhra including Pen-G facility
Updated On : 01 Apr 2024 | 10:39 AM IST

BJP biggest beneficiary of Aurobindo Pharma's Rs 52 cr electoral bonds

Aurobindo Pharma, one of whose directors was arrested in the Delhi liquor scam, had bought electoral bonds for a total of Rs 52 crore with more than half of it going to the Bharatiya Janata Party, according to data released by the Election Commission. The Hyderabad-based firm had purchased electoral bonds between April 3, 2021 to November 8, 2023 and Rs 34.5 crore was donated to the Bharatiya Janata Party (BJP), Rs 15 crore to the Bharat Rashtra Samithi (BRS), and Rs 2.5 crore to the Telugu Desam Party (TDP). The drug maker purchased electoral bonds worth Rs 5 crore on November 15, 2022 five days after one of its directors, P Sarath Chandra Reddy was arrested for involvement in money laundering linked to the controversial Delhi excise policy, which has been scrapped. Comments from the company could not be obtained. As per the Election Commission data, BJP encashed this sum on November 21, 2022. Last year in June, Reddy turned approver in the case after a Delhi court allowed him to

BJP biggest beneficiary of Aurobindo Pharma's Rs 52 cr electoral bonds
Updated On : 22 Mar 2024 | 10:06 PM IST

Aurobindo Pharma to start production of Pen-G at its Andhra plant in Q1FY25

Aurobindo Pharma expects its Rs 2,400 crore Pen-G (penicillin) plant in Andhra Pradesh to start trial production in April and commercial production in a couple of months and ramping up of production will happen during the second quarter of next fiscal, a senior official of the city-based drug maker has said. Santhanam Subramanian, Chief Financial Officer of Aurobindo Pharma, also said the company is constructing a total of 10 new facilities which are expected to capitalise in the next one to two years. Currently, the firm has a total of 25 manufacturing and packaging facilities at various locations. The plant, which was approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, will have a production capacity of around 15,000 tonnes annually. "We are doing the Pen-G project. We are in the process of installation and ...

Aurobindo Pharma to start production of Pen-G at its Andhra plant in Q1FY25
Updated On : 14 Mar 2024 | 1:03 PM IST

Will pharma stocks continue their dream rally in FY25?

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

Will pharma stocks continue their dream rally in FY25?
Updated On : 06 Mar 2024 | 2:09 PM IST

Markets are overvalued; IT, metals among most expensive sectors: Analysts

As of Jan 2024, the price-to-book valuation for the Nifty50 index, according to HDFC Securities Institutional Research, was 114 per cent of the average historical valuation, indicating expensiveness.

Markets are overvalued; IT, metals among most expensive sectors: Analysts
Updated On : 19 Feb 2024 | 9:18 AM IST

Aurobindo Pharma Q3 results: Profit up 91.43%, revenue rises 14.7%

The company's revenue from formulations increased by 17.2 per cent Y-o-Y to Rs 6,291 crore. Sequentially, it was up by 5.4 per cent from Rs 5,968 crore in Q2 FY24

Aurobindo Pharma Q3 results: Profit up 91.43%, revenue rises 14.7%
Updated On : 12 Feb 2024 | 6:39 PM IST

Aurobindo Pharma sinks 10% as formulation unit undergoes US FDA inspection

The inspection is under progress from January 22, 2024 and has not been concluded yet. Eugia Pharma is the company's injectables arm

Aurobindo Pharma sinks 10% as formulation unit undergoes US FDA inspection
Updated On : 01 Feb 2024 | 2:30 PM IST